Trial Profile

An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linzagolix (Primary)
Indications Adenomyosis; Uterine diseases
Focus Therapeutic Use
Sponsors ObsEva

Most Recent Events

20 Oct 2021 Primary endpoint (Change from baseline to week 24 in volume of the uterus with adenomyosis measured by Magnetic Resonance Imaging (MRI).) has been met according to an ObsEva media release
20 Oct 2021 According to an ObsEva media release, data from this study were presented at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo.
20 Oct 2021 Results published in the ObsEva Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com